This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Columbia-Suicide Severity Rating Scale | |
|---|---|
| Name | Columbia-Suicide Severity Rating Scale |
| Purpose | Suicide risk assessment |
| Developer | Columbia University Mailman School of Public Health |
| Introduced | 2007 |
Columbia-Suicide Severity Rating Scale
The Columbia-Suicide Severity Rating Scale is a clinician-administered tool designed to assess suicidal ideation and behavior. It is used across settings including emergency departments, psychiatric hospitals, schools, veterans' services and research studies, and has informed protocols in public health agencies and regulatory bodies. The instrument complements diagnostic evaluations by linking risk indicators to intervention decisions.
The scale operationalizes suicidal ideation and attempts for triage and monitoring in settings such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, Veterans Health Administration, World Health Organization, Centers for Disease Control and Prevention, and National Institutes of Health. It has been integrated into electronic health record initiatives at institutions like Kaiser Permanente and Mount Sinai Health System, and referenced by policy groups including American Psychiatric Association, Substance Abuse and Mental Health Services Administration, Joint Commission, and national suicide prevention strategies such as those in United Kingdom, Canada, Australia, New Zealand, Japan, and Germany.
Developed in the mid-2000s by researchers linked to Columbia University Mailman School of Public Health and collaborators from institutions such as New York State Psychiatric Institute, the scale emerged amid growing concern following high-profile cases and policy initiatives including responses to trends examined by National Suicide Prevention Lifeline, US Food and Drug Administration, and epidemiologic work at Harvard School of Public Health. Early validation studies involved cohorts from Children's Hospital of Philadelphia, Seattle Children's Hospital, University of Pittsburgh Medical Center, and veteran populations engaged by Veterans Affairs Boston Healthcare System. Subsequent dissemination drew support from organizations like American Foundation for Suicide Prevention and international partnerships including World Health Organization initiatives and multicenter studies at Karolinska Institutet and University College London.
The instrument comprises a set of standardized questions that distinguish between passive death wish, active suicidal ideation, intent, preparatory behavior, interrupted or aborted attempts, and actual attempts. Scoring yields categorical risk designations that inform decision trees used by clinical programs at centers such as Cleveland Clinic, UCLA Health, Stanford Health Care, and specialty units including adolescent programs at Children's National Hospital and forensic services at Bellevue Hospital. Versions include an adult clinician-administered form, an adolescent/youth adaptation used in school systems like New York City Department of Education, and a self-report module adopted in digital initiatives by Google Health pilots and university counseling centers at Columbia University and Yale University.
Administration protocols recommend trained personnel from disciplines represented at institutions such as Johns Hopkins Bloomberg School of Public Health, Oxford University, McGill University, and University of Melbourne administer the scale. Settings include emergency departments at Royal Brisbane Hospital, primary care networks like NHS England services, correctional facilities studied by Rikers Island research teams, and military contexts including programs at Walter Reed National Military Medical Center and Fort Bragg. The scale has been incorporated into crisis intervention workflows linked to helplines operated by groups such as Samaritans, Lifeline Australia, and the National Suicide Prevention Lifeline.
Psychometric evaluations at research centers including Columbia University, Vanderbilt University Medical Center, University of California, San Francisco, and University of Toronto reported evidence for concurrent validity, predictive validity for attempts, and interrater reliability across clinical and research populations. Meta-analytic reviews drawing on datasets from Addiction Research Centers, adolescent clinics at Stanford Children's Health, and veteran cohorts from VA Boston found variable sensitivity and specificity depending on sample characteristics, mirroring debates seen in methodological literature from Cochrane Collaboration and statistical guidance from CONSORT-aligned trials.
Clinically, the scale informs safety planning, hospitalization decisions, and brief interventions implemented at hospitals like Mount Sinai Hospital and community programs run by Mental Health America. In research, investigators at National Institute of Mental Health, Johns Hopkins University, University of Pennsylvania, and University College London use it as an outcome measure in trials of pharmacologic agents studied at centers such as Roche, Lundbeck, Eli Lilly and Company, and psychotherapy trials conducted at Rutgers University and University of Michigan. Public health surveillance efforts by Centers for Disease Control and Prevention and policy evaluations by Organisation for Economic Co-operation and Development have used aggregated C-SSRS data to inform prevention initiatives.
Critiques from academics at Yale School of Medicine, University of Oxford, Princeton University, and consumer advocacy groups such as National Alliance on Mental Illness highlight limitations including reliance on self-report, variability in interviewer training, cultural applicability in diverse settings like India and Brazil, and challenges in predicting rare events—a point emphasized in statistical critiques from scholars associated with Stanford University and Harvard University. Ethical and legal debates involving institutions like American Civil Liberties Union and regulatory scrutiny from US Food and Drug Administration address consequences of mandatory screening policies, potential for false positives in school-based screening at districts like Los Angeles Unified School District and resource constraints in low-income regions studied by Médecins Sans Frontières.
Category:Suicide prevention